← Back to patent-cliff list

Sepetaprost

Tier C — Watch / trade

Sepetaprost

-
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:PTGFR, PTGER3

Brand:セタネオ, SETANEO

Indications (approved):Ocular hypertension, Glaucoma

Regional status

US
Phase II
2014-05-01
EU
-
China
-
Japan
Approved
2025-08-25

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 16 · Total yield 74 mg
SEPETA-00169222-61-3SEPETA-00265025-95-8SEPETA-003197523-78-7SEPETA-00492134-19-5SEPETA-005627-15-6SEPETA-006—SEPETA-0071888410-60-3SEPETA-008—SEPETA-0091262872-71-8SEPETA-0101262872-72-9SEPETA-0111262872-73-0SEPETA-0121262872-74-1SEPETA-0131262872-75-2SEPETA-0141262872-77-4SEPETA-0151262872-78-5SEPETA-0161262872-79-6SEPETA-0171402924-07-5SEPETA-018—SEPETA-019112022-83-0SEPETA-020—API · Sepetaprost
CodeCAS No.Intermediate
SEPETA-00169222-61-3(3aR,4S,5R,6aS)-4-(hydroxymethyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-cyclopenta[b]furan-2-one
SEPETA-00265025-95-8(3aR,4S,5R,6aS)-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-cyclopenta[b]furan-2-one
SEPETA-003197523-78-7(3aR,4S,5R,6aS)-4-(((tert-butyldimethylsilyl)oxy)methyl)-5-((tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-cyclopenta[b]furan-2-ol
SEPETA-00492134-19-5(1S,2R,3S,4R)-2-allyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentan-1-ol
SEPETA-005627-15-6(E)-1,3-dibromoprop-1-ene
SEPETA-006-(((1S,2R,3S,5R)-2-allyl-3-(((Z)-3-bromoallyl)oxy)-5-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)methoxy)(tert-butyl)dimethylsilane
SEPETA-0071888410-60-3(4-ethoxy-4-oxobutyl)zinc(II) bromide
SEPETA-008-ethyl 6-(((1S,2R,3S,4R)-2-allyl-3-(((tert-butyldimethylsilyl)oxy)methyl)-4-((tetrahydro-2H-pyran-2-yl)oxy)cyclopentyl)oxy)hexanoate
SEPETA-0091262872-71-8ethyl 4-((5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0101262872-72-94-((5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl)butanoic acid
SEPETA-0111262872-73-0isopropyl 4-((5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)-5,5a,6,7,8,8a-hexahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0121262872-74-1isopropyl 4-((5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0131262872-75-2isopropyl 4-((3S,5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0141262872-77-4isopropyl 4-((3S,5aR,6S,7R,8aS)-6-(((tert-butyldimethylsilyl)oxy)methyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0151262872-78-5isopropyl 4-((3S,5aR,6S,7R,8aS)-6-(hydroxymethyl)-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0161262872-79-6isopropyl 4-((3S,5aR,6R,7R,8aS)-6-formyl-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-0171402924-07-5dimethyl (3-(2,5-difluorophenoxy)-2-oxopropyl)phosphonate
SEPETA-018-isopropyl 4-((3S,5aR,6R,7R,8aS)-6-((E)-4-(2,5-difluorophenoxy)-3-oxobut-1-en-1-yl)-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate
SEPETA-019112022-83-0Available(R)-1-methyl-3,3-diphenylhexahydropyrrolo[1,2-c][1,3,2]oxazaborole
SEPETA-020-isopropyl 4-((3S,5aR,6R,7R,8aS)-6-((R,E)-4-(2,5-difluorophenoxy)-3-hydroxybut-1-en-1-yl)-7-((tetrahydro-2H-pyran-2-yl)oxy)octahydro-2H-cyclopenta[b]oxepin-3-yl)butanoate

Frequently asked questions

What are the approved indications of Sepetaprost?

Approved indications include: Ocular hypertension, Glaucoma.

When does the Sepetaprost patent expire?

No public expiry year is available for Sepetaprost yet; this page updates once verified.

How many synthesis routes are recorded for Sepetaprost?

1 synthesis routes are recorded; the shortest is 16 steps with 74 mg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Sepetaprost intermediates?

1 intermediate CAS of Sepetaprost are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Sepetaprost intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-22